Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2014

Open Access 01-12-2014 | Research

Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitro

Authors: Lilan Chen, Ting Liu, Shu Zhang, Jinhua Zhou, Yunfei Wang, Wen Di

Published in: Journal of Ovarian Research | Issue 1/2014

Login to get access

Abstract

Background

Ovarian carcinoma is one of the most common gynecological cancers with high mortality rates. Numerous evidences demonstrate that cancer cells undergo metabolic abnormality during tumorigenesis in tumor microenvironment and further facilitate tumor progression. Succinate dehydrogenase (SDH or Complex II) is one of the important enzymes in the tricarboxylic acid (TCA) cycle. Succinate dehydrogenase subunit B (SDHB) gene, which encodes one of the four subunits of SDH, has been recognized as a tumor suppressor. However the role of SDHB in ovarian cancer is still unclear.

Methods

Using the SDHB specific siRNA and overexpression plasmid, the expression of SDHB was silenced and conversely induced in ovarian cancer cell lines SKOV3 and A2780, respectively. The possible role of SDHB in ovarian cancer was investigated in vitro, using proliferation, migration and invasion assays. To explore the mechanism, proliferation and migration related proteins such as Bcl-2, cleaved caspase 3, p-ERK, MMP-2, and p-FAK were examined by western blot. P-P38, p-AMPKα, and HIF-1α were also examined by western blot. CoCl2 was used to induce HIF-1α expression in SKOV3 and A2780 cells.

Results

SDHB silencing promoted cell proliferation, invasion, and migration, but inhibited apoptosis of SKOV3 and A2780 cells. In contrast, overexpression of SDHB inhibited cell proliferation, invasion, migration, and promoted apoptosis in SKOV3 cells. It was observed that up-regulation of Bcl-2 and MMP-2, activation of p-P38, p-ERK, and p-FAK, inhibition of cleaved caspase 3 in SDHB-silenced cells. Meanwhile, decreased Bcl-2 and MMP-2, inhibition of p-P38, p-ERK, and p-FAK, activation of cleaved caspase 3 were shown in SDHB-overexpressed SKOV3 cells. HIF-1α, an essential factor in tumor progression, was up-regulated in SDHB-silenced cells with the activation of p-AMPKα and down-regulated in SDHB-overexpressed cancer cells with the decreased p-AMPKα. And SDHB was proved to be decreased due to upregulation of HIF-1α expression in CoCl2-treated cancer cells.

Conclusions

Our results firstly revealed that SDHB played a key role in cell proliferation, invasion, migration, and apoptosis of human ovarian carcinoma via AMPK-HIF-1α pathway. SDHB-overexpression might be a new approach to inhibit tumor progression in human ovarian carcinoma.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG: Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012,120(3):612–618. 10.1097/AOG.0b013e318264f794CrossRefPubMed
4.
Zhu J, Zhang S, Gu L, Di W: Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. Carcinogenesis 2012,33(12):2334–2343. 10.1093/carcin/bgs278CrossRefPubMed
5.
6.
Favier J, Briere JJ, Strompf L, Amar L, Filali M, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 2005,63(4):171–179. 10.1159/000084685CrossRefPubMed
7.
Baysal BE: On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 2003,14(10):453–459. 10.1016/j.tem.2003.08.004CrossRefPubMed
8.
Gaal J, Stratakis CA, Carney JA, Ball ER, Korpershoek E, Lodish MB, Levy I, Xekouki P, van Nederveen FH, den Bakker MA: SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 2011,24(1):147–151. 10.1038/modpathol.2010.185PubMedCentralCrossRefPubMed
9.
Kusao I, Troelstrup D, Shiramizu B: Possible Mitochondria-Associated Enzymatic Role in Non-Hodgkin Lymphoma Residual Disease. Cancer Growth Metastasis 2008, 1: 3–8.PubMedCentralPubMed
10.
Zhang D, Wang W, Xiang B, Li N, Huang S, Zhou W, Sun Y, Wang X, Ma J, Li G: Reduced succinate dehydrogenase B expression is associated with growth and de-differentiation of colorectal cancer cells. Tumour Biol 2013,34(4):2337–2347. 10.1007/s13277-013-0781-4CrossRefPubMed
11.
Blank A, Schmitt AM, Korpershoek E, van Nederveen F, Rudolph T, Weber N, Strebel RT, de Krijger R, Komminoth P, Perren A: SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling. Endocr Relat Cancer 2010,17(4):919–928. 10.1677/ERC-09-0316CrossRefPubMed
12.
Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P, Rotig A, Jeunemaitre X: The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001,69(6):1186–1197. 10.1086/324413PubMedCentralCrossRefPubMed
13.
Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, Rotig A, Jeunemaitre X: Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002,87(10):4771–4774. 10.1210/jc.2002-020525CrossRefPubMed
14.
Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS: A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005,1(1):72–80. 10.1371/journal.pgen.0010008CrossRefPubMed
15.
Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ: Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005,14(15):2231–2239. 10.1093/hmg/ddi227CrossRefPubMed
16.
Allen M, Louise Jones J: Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011,223(2):162–176. 10.1002/path.2803CrossRefPubMed
17.
18.
Chen CL, Chu JS, Su WC, Huang SC, Lee WY: Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch 2010,457(1):53–61. 10.1007/s00428-010-0938-0CrossRefPubMed
19.
Zhu P, Ning Y, Yao L, Chen M, Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res 2010, 29: 124. 10.1186/1756-9966-29-124PubMedCentralCrossRefPubMed
20.
Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z, Wan Y, Di W: Hypoxia inducible factor 1alpha-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol 2013,42(5):1578–1588.PubMedCentralPubMed
21.
Yeh YM, Chuang CM, Chao KC, Wang LH: MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer 2013,133(4):867–878. 10.1002/ijc.28086CrossRefPubMed
22.
Shackelford DB, Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009,9(8):563–575. 10.1038/nrc2676PubMedCentralCrossRefPubMed
23.
Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B: AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013,17(1):113–124. 10.1016/j.cmet.2012.12.001PubMedCentralCrossRefPubMed
24.
Cervera AM, Apostolova N, Crespo FL, Mata M, McCreath KJ: Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Res 2008,68(11):4058–4067. 10.1158/0008-5472.CAN-07-5580CrossRefPubMed
25.
Fujii N, Jessen N, Goodyear LJ: AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab 2006,291(5):E867–877. 10.1152/ajpendo.00207.2006CrossRefPubMed
26.
Hardie DG: The AMP-activated protein kinase pathway–new players upstream and downstream. J Cell Sci 2004,117(Pt 23):5479–5487. 10.1242/jcs.01540CrossRefPubMed
27.
Shaw RJ: Glucose metabolism and cancer. Curr Opin Cell Biol 2006,18(6):598–608. 10.1016/j.ceb.2006.10.005CrossRefPubMed
28.
Li J, Miller EJ, Ninomiya-Tsuji J, Russell RR 3rd, Young LH: AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 2005,97(9):872–879. 10.1161/01.RES.0000187458.77026.10CrossRefPubMed
29.
Pelletier A, Joly E, Prentki M, Coderre L: Adenosine 5'-monophosphate-activated protein kinase and p38 mitogen-activated protein kinase participate in the stimulation of glucose uptake by dinitrophenol in adult cardiomyocytes. Endocrinology 2005,146(5):2285–2294. 10.1210/en.2004-1565CrossRefPubMed
30.
Fremin C, Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010, 3: 8. 10.1186/1756-8722-3-8PubMedCentralCrossRefPubMed
31.
Meloche S, Pouyssegur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007,26(22):3227–3239. 10.1038/sj.onc.1210414CrossRefPubMed
32.
Poulikakos PI, Solit DB: Resistance to MEK inhibitors: should we co-target upstream? Sci Signal 2011,4(166):e16. 10.1126/scisignal.2001948CrossRef
33.
Schlaepfer DD, Mitra SK, Ilic D: Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 2004,1692(2–3):77–102. 10.1016/j.bbamcr.2004.04.008CrossRefPubMed
34.
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC: The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005,5(7):505–515. 10.1038/nrc1647CrossRefPubMed
35.
Hoekstra R, Eskens FA, Verweij J: Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001,6(5):415–427. 10.1634/theoncologist.6-5-415CrossRefPubMed
36.
Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001,82(2):291–298. 10.1006/gyno.2001.6243CrossRefPubMed
37.
Hsu CC, Wang CH, Wu LC, Hsia CY, Chi CW, Yin PH, Chang CJ, Sung MT, Wei YH, Lu SH: Mitochondrial dysfunction represses HIF-1alpha protein synthesis through AMPK activation in human hepatoma HepG2 cells. Biochim Biophys Acta 2013,1830(10):4743–4751. 10.1016/j.bbagen.2013.06.004CrossRefPubMed
38.
McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989,57(1):79–88. 10.1016/0092-8674(89)90174-8CrossRefPubMed
39.
Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988,335(6189):440–442. 10.1038/335440a0CrossRefPubMed
40.
Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000,102(1):1–4. 10.1016/S0092-8674(00)00003-9CrossRefPubMed
41.
Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH: Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 2013, 14: 32. 10.1186/1471-2121-14-32PubMedCentralCrossRefPubMed
42.
Fidler IJ, Radinsky R: Genetic control of cancer metastasis. J Natl Cancer Inst 1990,82(3):166–168. 10.1093/jnci/82.3.166CrossRefPubMed
43.
Tester AM, Ruangpanit N, Anderson RL, Thompson EW: MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis 2000,18(7):553–560. 10.1023/A:1011953118186CrossRefPubMed
44.
Luo M, Guan JL: Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 2010,289(2):127–139. 10.1016/j.canlet.2009.07.005PubMedCentralCrossRefPubMed
45.
Cassavaugh J, Lounsbury KM: Hypoxia-mediated biological control. J Cell Biochem 2011,112(3):735–744. 10.1002/jcb.22956CrossRefPubMed
46.
Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009,324(5930):1029–1033. 10.1126/science.1160809PubMedCentralCrossRefPubMed
47.
Shin JM, Jeong YJ, Cho HJ, Park KK, Chung IK, Lee IK, Kwak JY, Chang HW, Kim CH, Moon SK: Melittin suppresses HIF-1alpha/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One 2013,8(7):e69380. 10.1371/journal.pone.0069380PubMedCentralCrossRefPubMed
48.
He G, Jiang Y, Zhang B, Wu G: The effect of HIF-1alpha on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr 2014,23(1):174–180.PubMed
49.
Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET 3rd: HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 2013,123(5):2078–2093. 10.1172/JCI66715PubMedCentralCrossRefPubMed
50.
Karna E, Szoka L, Palka J: Thrombin-dependent modulation of beta1-integrin-mediated signaling up-regulates prolidase and HIF-1alpha through p-FAK in colorectal cancer cells. Mol Cell Biochem 2012,361(1–2):235–241. 10.1007/s11010-011-1108-7CrossRefPubMed
Metadata
Title
Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitro
Authors
Lilan Chen
Ting Liu
Shu Zhang
Jinhua Zhou
Yunfei Wang
Wen Di
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-014-0115-1

Other articles of this Issue 1/2014

Journal of Ovarian Research 1/2014 Go to the issue

Case report

Sertoli-Leydig cell tumor with unique nail findings in a post-menopausal woman: a case report and literature review

Research

Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression

Research

Positive effects of prolonged caloric restriction on the population of very small embryonic-like stem cells – hematopoietic and ovarian implications

Research

Suppression of GNAI2 message in ovarian cancer

Research

Locally existing endothelial cells and pericytes in ovarian stroma, but not bone marrow-derived vascular progenitor cells, play a central role in neovascularization during follicular development in mice

Research

Association between circulating adiponectin levels and polycystic ovarian syndrome